Core Insights - The stock of Beijing Baipusi Biotechnology Co., Ltd. (百普赛斯) experienced a slight increase of 0.41% on November 6, with a trading volume of 70.91 million yuan [1] - The company reported a financing buy amount of 2.68 million yuan and a financing repayment of 3.83 million yuan on the same day, resulting in a net financing buy of -1.15 million yuan [1] - As of November 6, the total margin balance for Baipusi was 115 million yuan, indicating a high level of financing activity [1] Financing Overview - On November 6, Baipusi had a financing buy of 2.68 million yuan, with a current financing balance of 114 million yuan, which represents 1.13% of its market capitalization [1] - The financing balance is above the 90th percentile of the past year, indicating a high level of leverage [1] - In terms of securities lending, Baipusi repaid 900 shares on November 6, with no shares sold, resulting in a lending balance of 34.54 thousand yuan, which is below the 40th percentile of the past year [1] Business Performance - As of September 30, Baipusi had 10,600 shareholders, a decrease of 9.75% from the previous period, while the average number of circulating shares per person increased by 54.93% to 11,947 shares [2] - For the period from January to September 2025, Baipusi achieved a revenue of 613 million yuan, representing a year-on-year growth of 32.26%, and a net profit attributable to shareholders of 132 million yuan, up 58.61% year-on-year [2] Dividend and Shareholding Structure - Since its A-share listing, Baipusi has distributed a total of 432 million yuan in dividends, with 312 million yuan distributed over the past three years [3] - As of September 30, 2025, the second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 13.56 million shares, an increase of 7.57 million shares from the previous period [3] - Other notable shareholders include China Europe Medical Health Mixed A and China Europe Medical Innovation Stock A, with significant increases in their holdings [3]
百普赛斯11月6日获融资买入268.22万元，融资余额1.14亿元